Literature DB >> 3109335

Serum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection.

M M Brett, A T Ghoneim, J M Littlewood.   

Abstract

Serum IgG antibodies to Pseudomonas aeruginosa surface antigens were measured by enzyme linked immunosorbent assay in all patients with cystic fibrosis from whom P. aeruginosa was isolated for the first time during a study period of 18 months. In 15 patients the titre of serum IgG antibodies was greater than control values before or at the time of the first bacteriological isolation of P. aeruginosa. The presence of serum antibodies specific to P. aeruginosa suggests exposure to infection by that organism for some months before its isolation in significant numbers from the respiratory tract. In the other two patients serum titres were within the control range before isolation of P. aeruginosa but had increased to above the control range within the next month. Longitudinal studies on the entire group of patients showed further increases in titre concurrently with further isolations of P. aeruginosa. These results suggest that this assay may be an indicator of the beginning of pulmonary infection by P. aeruginosa and may prove to be a sensitive monitor of the progress of infection, and response to treatment, during the first months of infection by that organism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109335      PMCID: PMC1778335          DOI: 10.1136/adc.62.4.357

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  22 in total

1.  The systematic evaluation of the chest radiograph in cystic fibrosis.

Authors:  A R Chrispin; A P Norman
Journal:  Pediatr Radiol       Date:  1974

2.  Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71.

Authors:  M B Mearns; G H Hunt; R Rushworth
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

3.  Sequence variability of rabbit antibody light chains. Familial occurrence of n-terminal sequence differences between b4 and b9 light chains.

Authors:  A L Thunberg; T J Kindt
Journal:  Scand J Immunol       Date:  1975       Impact factor: 3.487

4.  Monoclonal antibodies against Pseudomonas aeruginosa outer membrane antigens: isolation and characterization.

Authors:  R E Hancock; A A Wieczorek; L M Mutharia; K Poole
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

Review 5.  Chemical cross-linking: reagents and problems in studies of membrane structure.

Authors:  K Peters; F M Richards
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

6.  Antibacterial precipitins and autoantibodies in serum of patients with cystic fibrosis.

Authors:  N Høiby; A Wiik
Journal:  Scand J Respir Dis       Date:  1975-05

7.  Rapid diagnosis of Pseudomonas aeruginosa urinary tract infections by radioimmunoassay.

Authors:  R B Kohler; L J Wheat; A White
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

8.  Reaginic antibody production to protein antigens of Escherichia coli and Pseudomonas aeruginosa by mice.

Authors:  P J Danneman; J G Michael
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

9.  Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis.

Authors:  N Hoiby; E W Flensborg; B Beck; B Friis; S V Jacobsen; L Jacobsen
Journal:  Scand J Respir Dis       Date:  1977-04

10.  Outer membrane proteins of Pseudomonas aeruginosa serotype strains.

Authors:  L M Mutharia; T I Nicas; R E Hancock
Journal:  J Infect Dis       Date:  1982-12       Impact factor: 5.226

View more
  15 in total

1.  Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

2.  Pseudomonas serology: confusion, controversy, and challenges.

Authors:  P M Farrell; J R W Govan
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

3.  Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine.

Authors:  P E Makidon; J Knowlton; J V Groom; L P Blanco; J J LiPuma; A U Bielinska; J R Baker
Journal:  Med Microbiol Immunol       Date:  2009-12-06       Impact factor: 3.402

4.  Pseudomonas infections in cystic fibrosis.

Authors:  R H George
Journal:  Arch Dis Child       Date:  1987-05       Impact factor: 3.791

5.  Serum IgG antibodies to Pseudomonas aeruginosa in intensive care adult patients.

Authors:  R Cohendy; B Perrin; J L Vaille; H Mion
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

6.  An ELISA to detect antipseudomonal IgA antibodies in sera of patients with cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

7.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

8.  Pseudomonas aeruginosa antibodies in blood spots from patients with cystic fibrosis.

Authors:  V Thanasekaraan; M S Wiseman; R J Rayner; E J Hiller; D J Shale
Journal:  Arch Dis Child       Date:  1989-11       Impact factor: 3.791

9.  Immunoproteomics to examine cystic fibrosis host interactions with extracellular Pseudomonas aeruginosa proteins.

Authors:  Hamish G Upritchard; Stuart J Cordwell; Iain L Lamont
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

10.  Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.